WallStreetZenWallStreetZen

NASDAQ: VYNE
Vyne Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for VYNE

Based on 1 analyst offering 12 month price targets for Vyne Therapeutics Inc.
Min Forecast
$5.75+123.74%
Avg Forecast
$5.75+123.74%
Max Forecast
$5.75+123.74%

Should I buy or sell VYNE stock?

Based on 1 analyst offering ratings for Vyne Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VYNE stock forecasts and price targets.

VYNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-29

1 of 1

Forecast return on equity

Is VYNE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is VYNE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VYNE revenue forecast

What is VYNE's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$400.0k-5.66%
Avg 2 year Forecast
$13.6M+3,107.55%
VYNE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VYNE revenue growth forecast

How is VYNE forecast to perform vs Biotechnology companies and vs the US market?
Company
479.5%
Industry
37.5%
Market
10.08%
VYNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VYNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VYNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VYNE$2.57$5.75+123.74%Buy
UNCY$1.04$5.63+440.87%Strong Buy
OKYO$1.41$7.00+396.45%Buy
XLO$1.06N/AN/A
CARA$0.67$4.63+588.24%Buy
View Top Biotech Stocks

Vyne Therapeutics Stock Forecast FAQ

Is Vyne Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VYNE) stock is to Buy VYNE stock.

Out of 1 analyst, 0 (0%) are recommending VYNE as a Strong Buy, 1 (100%) are recommending VYNE as a Buy, 0 (0%) are recommending VYNE as a Hold, 0 (0%) are recommending VYNE as a Sell, and 0 (0%) are recommending VYNE as a Strong Sell.

If you're new to stock investing, here's how to buy Vyne Therapeutics stock.

What is VYNE's revenue growth forecast for 2024-2028?

(NASDAQ: VYNE) Vyne Therapeutics's forecast annual revenue growth rate of 479.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Vyne Therapeutics's revenue in 2024 is $424,000.On average, 1 Wall Street analysts forecast VYNE's revenue for 2024 to be $5,639,555, with the lowest VYNE revenue forecast at $5,639,555, and the highest VYNE revenue forecast at $5,639,555.

In 2028, VYNE is forecast to generate $191,744,877 in revenue, with the lowest revenue forecast at $191,744,877 and the highest revenue forecast at $191,744,877.

What is VYNE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VYNE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VYNE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VYNE price target, the average VYNE price target is $5.75, with the highest VYNE stock price forecast at $5.75 and the lowest VYNE stock price forecast at $5.75.

The Wall Street analyst predicted that Vyne Therapeutics's share price could reach $5.75 by Feb 28, 2025. The average Vyne Therapeutics stock price prediction forecasts a potential upside of 123.74% from the current VYNE share price of $2.57.

What is VYNE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VYNE) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.